by Dale Harrison | Jan 24, 2023 | Press Releases
Noninvasive Test Developed Using Machine Learning Detects Early-Stage Lung Cancer with High Sensitivity and Specificity SAN ANTONIO, TX – Jan 24, 2023 – – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) today announced publication of “Detection of early-stage...
by Dale Harrison | Jan 23, 2023 | Publications
Respiratory Research, January 21, 2023 Authors Lemieux, M.E., Reveles, X.T., Rebeles, J. et al. Abstract Background Low-dose spiral computed tomography (LDCT) may not lead to a clear treatment path when small to intermediate-sized lung nodules are identified....
by Dale Harrison | Jan 4, 2023 | Press Releases
SAN ANTONIO, TX – Jan 4, 2023 – bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced today that the U.S. Patent and Trademark Office (USPTO) has provided a Notice of Allowance for a patent application titled “Porphyrin Compounds and Compositions Useful for...
by Dale Harrison | Dec 28, 2022 | Articles, News
Meet BioAffinity Technologies: Fly exclusive interview with CEO Maria Zannes DECEMBER 28, 2022 As published in the The Fly By: Jessica de Sa-Mota BioAffinity focuses on the development of noninvasive, early-stage cancer diagnosis and targeted cancer treatment In an...
by Dale Harrison | Dec 28, 2022 | Events
December 30, 2022 bioAffinity President & CEO Maria Zannes will meet with the institutional investors and investment banking groups while attending the WuXi Global Forum “Advancing Breakthroughs for Patients” during the J.P. Morgan 41st Annual Healthcare...
